KOREA WHO

Huh Eun-chul is the President and CEO of GC Biopharma.

After two attempts, he successfully began the overseas expansion by launching the sale of the blood-derived immune deficiency treatment, 'Aliglo,' in the U.S.

He is also focusing on developing vaccines and treatments for rare diseases, thereby expanding GC Biopharma's business scope.

Huh was born on February 23, 1972, in Seoul as the second son of Huh Young-sup, former chairman of GC Biopharma, and his wife, Jung In-ae. His grandfather, Huh Chae-kyung, was the founder of Hanil Cement.

He graduated from Yeongdong High School in Seoul and earned a degree in food engineering from Seoul National University. He also completed a master’s degree in biochemical engineering at Seoul National University’s graduate school and pursued a Ph.D. in food engineering at Cornell University.

Huh joined GC Biopharma’s Corporate Planning Office and mainly worked in research and development (R&D). After holding positions as managing director and senior managing director of the R&D Planning Office, he expanded his role as Chief Technology Officer (CTO). Later, he oversaw overall management as the head of the Corporate Coordination Office.

He initially led GC Biopharma as a co-CEO alongside Vice Chairman Cho Soon-tae. When Cho stepped down, Huh became the sole CEO, assuming full responsibility for managing the company.

He is a devout Christian.

Known for his dislike of rigid formalities, Huh promotes a horizontal organizational culture and is regarded among employees as a symbol of youthfulness and open communication.

#GCBiopharma #HuhEunchul #CEO #pharmaceuticals #Aliglo #rareDiseases #immunodeficiency #biotech #innovation #corporateLeadership